ACRV - Company ID 0001781174
The table below shows Acrivon Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$20.54M | -$19.54M | -$17.08M | -$11.36M | -$8.42M |
| Capital expenditure | $14.00K | $58.00K | $815.00K | $25.00K | $415.00K |
| Investing cash flow | $13.13M | $19.21M | $5.85M | $9.33M | -$415.00K |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | - |
Acrivon Therapeutics, Inc. reported operating cash flow of -$63.66M for fiscal year 2025. That is up 3.1% from -$65.67M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$13.98M (FY 2021) to -$63.66M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Financing cash flow | -$33.00K | -$343.00K | -$172.00K | - | - |